LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment

The oncolytic peptide LTX-315, which has been designed based on structure-activity relationship studies of host defense peptides, has the ability to kill human cancer cells and induce specific anticancer immune response when injected locally into tumors established in immunocompetent mice. The oncol...

Full description

Saved in:
Bibliographic Details
Published in:Future medicinal chemistry 2017-08, Vol.9 (12), p.1339-1344
Main Authors: Sveinbjørnsson, Baldur, Camilio, Ketil Andre, Haug, Bengt Erik, Rekdal, Øystein
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
cancer
Cell Membrane - drug effects
Cell Membrane - immunology
Cell Proliferation - drug effects
Chemistry: 440
DAMP
Humans
immunotherapy
Kjemi: 440
Matematikk og Naturvitenskap: 400
Mathematics and natural science: 400
Mice
Mitochondria - drug effects
Mitochondria - immunology
Neoplasms - drug therapy
Neoplasms - immunology
Oligopeptides - chemistry
Oligopeptides - pharmacology
oncolytic peptide
Tumor Microenvironment - drug effects
Tumor Microenvironment - immunology
VDP
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The oncolytic peptide LTX-315, which has been designed based on structure-activity relationship studies of host defense peptides, has the ability to kill human cancer cells and induce specific anticancer immune response when injected locally into tumors established in immunocompetent mice. The oncolytic effect of LTX-315 involves perturbation of plasma membrane and the mitochondria with subsequent release of danger-associated molecular pattern molecules, which highlights the ability of LTX-315 to induce complete regression and protective immune responses. Treatment with LTX-315 reprograms the tumor microenvironment by decreasing the local abundance of immunosuppressive cells and by increasing the frequency of effector T cells.
ISSN:1756-8919
1756-8927
1756-8927
DOI:10.4155/fmc-2017-0088